Covance Opens New Clinical Development Offices in Brazil and Mexico
September 09 2009 - 11:11AM
PR Newswire (US)
- Broader Latin American presence increases access to patients to
help reduce drug development timelines - PRINCETON, N.J., Sept. 9
/PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today announced
the opening of new clinical development offices in Sao Paolo,
Brazil and Mexico City, Mexico. These offices further expand
Covance's global footprint with a comprehensive range of services
across Latin America. Earlier this year, Covance announced new
offices in Santiago, Chile and Lima, Peru. These new sites will
support staff in these countries, Central America, and the
Caribbean, as well as the regional network of field-based clinical
research associates in the region. Covance has been providing
clinical trial support in Latin America since 1997 with the
company's first office in Buenos Aires, Argentina. Operations in
the region expanded quickly through a network of regional clinical
trial monitors trained and supervised under guidelines meeting both
local and international regulatory requirements as well as global
Covance quality standards. "Our continued expansion in Latin
America highlights the region's growing significance in Covance's
clinical development service offerings. These new offices increase
our access to patients who are currently not receiving medical
therapies and will enable us to shorten clinical trial cycle times
for our pharmaceutical and biotech clients," said Wayne Langlois,
vice president and general manager of global clinical development
services at Covance. "The clinical trials we conduct in Latin
America are part of a carefully weighted site selection approach
that not only produces high-quality data on time, but also
satisfies the requirements of regulatory authorities," said Katie
Margules, senior director for Latin America. Covance offers
clinical development services for Phase I to III clinical trials in
more than 55 countries which include emerging markets across Asia
Pacific, Central and Eastern Europe, and Latin America. With a full
suite of services to take a drug through all stages of development,
Covance offers extensive clinical and therapeutic expertise, global
reach, proactive project management, and strong investigator site
relationships to consistently deliver high quality data on time.
About Covance Covance, with headquarters in Princeton, New Jersey,
is one of the world's largest and most comprehensive drug
development services companies with annual revenues greater than
$1.7 billion, global operations in more than 25 countries, and more
than 10,000 employees worldwide. Information on Covance's products
and services, recent press releases, and SEC filings can be
obtained through its website at http://www.covance.com/. Statements
contained in this press release, which are not historical facts,
are forward-looking statements pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
All such forward-looking statements including the statements
contained herein regarding anticipated trends in the Company's
business are based largely on management's expectations and are
subject to and qualified by risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by such statements. These risks and uncertainties include,
without limitation, competitive factors, outsourcing trends in the
pharmaceutical industry, levels of industry research and
development spending, the Company's ability to continue to attract
and retain qualified personnel, the fixed price nature of contracts
or the loss of large contracts, and other factors described in the
Company's filings with the Securities and Exchange Commission.
DATASOURCE: Covance Inc. CONTACT: Alicia Agugliaro, Media
Relations, +1-609-452-4275, or Investor Relations, +1-609-452-4807,
both of Covance Inc. Web Site: http://www.covance.com/
Copyright